Bio-Rad Laboratories, Inc. (NYSE:BIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. “

Several other equities research analysts also recently commented on the company. Deutsche Bank AG reaffirmed a “buy” rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a report on Monday, September 18th. TheStreet downgraded Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price for the company. Finally, BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Bio-Rad Laboratories has an average rating of “Buy” and an average target price of $240.00.

Shares of Bio-Rad Laboratories (NYSE BIO) opened at 223.27 on Wednesday. The stock has a market cap of $6.62 billion, a PE ratio of 441.25 and a beta of 0.91. The company’s 50-day moving average price is $221.08 and its 200-day moving average price is $219.92. Bio-Rad Laboratories has a 52-week low of $154.89 and a 52-week high of $242.79.

TRADEMARK VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) Stock Rating Upgraded by Zacks Investment Research” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/bio-rad-laboratories-inc-bio-stock-rating-upgraded-by-zacks-investment-research/1611654.html.

In related news, EVP Michael Crowley sold 700 shares of the stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the completion of the sale, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at approximately $444,774.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 28.29% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in BIO. Canada Pension Plan Investment Board purchased a new stake in Bio-Rad Laboratories in the 2nd quarter worth about $113,000. Pacad Investment Ltd. purchased a new stake in Bio-Rad Laboratories in the 2nd quarter worth about $113,000. Turner Investments LLC purchased a new stake in Bio-Rad Laboratories in the 2nd quarter worth about $136,000. Capital Analysts LLC purchased a new stake in Bio-Rad Laboratories in the 2nd quarter worth about $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Bio-Rad Laboratories by 12.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock worth $184,000 after acquiring an additional 90 shares in the last quarter. 62.84% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.